Dr. Jason R. Westin's research focuses on developing therapeutic strategies for lymphoma.
Patients facing a relapse of diffuse large B-cell lymphoma often encounter complex choices about their next steps in treatment.
Here, Dr. Jason Westin contextualizes the latest development in CAR T-Cell Therapy, a groundbreaking new treatment for patients with a relapse of diffuse large B-cell lymphoma. Dr. Jason Westin is an oncologist at MD Anderson Cancer Center, where he serves as Director of the Lymphoma Clinical Research Program.
Dr. Jason Westin
MD Anderson Cancer Center
Over the past decade, cell therapies — particularly chimeric antigen receptor T-cell (CAR T) therapies — have shown remarkable efficacy in treating hematological malignancies.
Sign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.
